Turning Point Therapeutics (TPTX) Stock Price, News & Analysis

Company Overview

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $76.01 to $76.01
• 50-Day Range: $74.80 to $76.01
• 52-Week Range: $23.77 to $82.20
• Volume: 4,322 shs
• Average Volume: 1.14 million shs
• Market Capitalization: $3.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TPTX Stock Analysis - Frequently Asked Questions

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The business had revenue of $0.46 million for the quarter.

When did Turning Point Therapeutics IPO?

Turning Point Therapeutics (TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Turning Point Therapeutics investors own include Meta Platforms (META), Diamondback Energy (FANG), Gilead Sciences (GILD), HubSpot (HUBS), Netflix (NFLX), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 7/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TPTX
• CIK: 1595893
• Web: www.tptherapeutics.com
• Phone: (858) 926-5251
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($6.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$236.55 million
• Net Margins: N/A
• Pretax Margin: -33,959.03%
• Return on Equity: -37.45%
• Return on Assets: -35.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.83
• Quick Ratio: 16.83

Sales & Book Value

• Annual Sales: $30.83 million
• Price / Sales: 123.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.84 per share
• Price / Book: 4.80

Miscellaneous

• Outstanding Shares: 50,074,000
• Free Float: 45,768,000
• Market Cap: $3.81 billion
• Optionable: Not Optionable
• Beta: -0.18